Clinical trial
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic…
NCT00147901 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00147901 |
|---|---|
| Title | Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) |
| Official title | Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG) |
| Lead sponsor | German CLL Study Group, Other |
| Collaborators | University of Cologne MedacSchering Onkologie |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | FCCam |
| Enrollment | 61 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2011 |
| First posted | Sep 7, 2005 |
| Last update posted | Oct 3, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: